company background image
HZNP logo

Horizon Therapeutics NasdaqGS:HZNP Stock Report

Last Price

US$116.30

Market Cap

US$26.6b

7D

0.06%

1Y

82.8%

Updated

10 Oct, 2023

Data

Company Financials +

Horizon Therapeutics Public Limited Company

NasdaqGS:HZNP Stock Report

Market Cap: US$26.6b

HZNP Stock Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.

HZNP fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance1/6
Financial Health6/6
Dividends0/6

Horizon Therapeutics Public Limited Company Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Horizon Therapeutics
Historical stock prices
Current Share PriceUS$116.30
52 Week HighUS$116.38
52 Week LowUS$60.03
Beta1.01
1 Month Change0.76%
3 Month Change12.37%
1 Year Change82.80%
3 Year Change45.18%
5 Year Change505.10%
Change since IPO1,171.04%

Recent News & Updates

Recent updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Nov 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon pays HemoShear milestone payment under pact to develop gout therapies

Sep 21

Horizon Therapeutics announces $500M buyback program

Sep 09

Horizon Therapeutics to expand footprint in Ireland

Aug 29

Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Aug 22
Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Horizon Therapeutics: This Core Biotech Company Is On Sale

Aug 19

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Aug 04
Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Aug 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

Jul 31

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Jul 08

Shareholder Returns

HZNPUS BiotechsUS Market
7D0.06%0.9%0.4%
1Y82.8%10.3%28.8%

Return vs Industry: HZNP exceeded the US Biotechs industry which returned -4.2% over the past year.

Return vs Market: HZNP exceeded the US Market which returned 14.1% over the past year.

Price Volatility

Is HZNP's price volatile compared to industry and market?
HZNP volatility
HZNP Average Weekly Movement2.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: HZNP has not had significant price volatility in the past 3 months.

Volatility Over Time: HZNP's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20052,190Tim Walberthttps://www.horizontherapeutics.com

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use.

Horizon Therapeutics Public Limited Company Fundamentals Summary

How do Horizon Therapeutics's earnings and revenue compare to its market cap?
HZNP fundamental statistics
Market capUS$26.63b
Earnings (TTM)US$438.00m
Revenue (TTM)US$3.64b

60.8x

P/E Ratio

7.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HZNP income statement (TTM)
RevenueUS$3.64b
Cost of RevenueUS$824.98m
Gross ProfitUS$2.82b
Other ExpensesUS$2.38b
EarningsUS$438.00m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.91
Gross Margin77.36%
Net Profit Margin12.02%
Debt/Equity Ratio48.2%

How did HZNP perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.